Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents

Fleischhaker, Christian; Heiser, Philip; Hennighausen, Klaus; Herpertz‐Dahlmann, Beate; Holtkamp, Kristian; Mehler-Wex, Claudia; Rauh, Reinhold; Remschmidt, Helmut; Schulz, Eberhard; Warnke, Andreas

doi:10.1007/s00702-006-0602-7

Cited by 53 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings of a 5.5-kg weight gain in 6 months are similar to previous study findings (Kelly et al 1998;Martin et al 2000;Fleischhaker et al 2007). Recently, Correll et al (2009) studied cardiometabolic effects of second-generation antipsychotics, including risperidone, in 272 pediatric patients (aged 4-19 years).…”

supporting

confidence: 94%

Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey

Erdoğan

Karaman²,

Özdemir³

et al. 2010

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

These findings suggest that risperidone treatment in the long term commonly leads to liver function changes, although at therapeutic doses in children and adolescents it may rarely induce a serious hepatic toxicity. Concomitant use of antidepressants and methylphenidate and variations in age and pubertal status are limitations of present study. Further studies are needed to assess the importance and role of other variables over LFT abnormalities in youth population.

show abstract

supporting

confidence: 94%

Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey

Erdoğan

Karaman²,

Özdemir³

et al. 2010

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Additionally, the currently available antipsychotic drugs exhibit various degrees of metabolic and endocrine abnormalities. Clozapine and risperidone are in particular associated with significant weight gain, especially in children and adolescents [195]. Aripiprazole exhibits relatively less metabolic side-effects than other commonly used atypical antipsychotic drugs [196], but at an increased risk for akathisia.…”

Section: Comparison Of Representative Antipsychotics Haloperidol CLmentioning

confidence: 99%

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Snyder²,

Vanover³

2016

CTMC

219

141

View full text Add to dashboard Cite

Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approximately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demonstrate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the unintentional engagement of multiple pharmacological targets or even the excessive engagement of intended pharmacological targets can lead to undesired consequences and poor tolerability. In this article, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia. Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metabolism and safety, pharmacological properties, preclinical data in animal models, clinical outcomes and associated side effects.

show abstract

“…However, weight gain is an important adverse effect of risperidone, particularly for children (Safer 2004), mean gains being in the range of 2.2-2.8 kg in the first 8 weeks of treatment in controlled studies (Findling et al 2004;Shea et al 2004;Troost et al 2005;Fleischhaker et al 2007). Weight gain has well-established health risks, which may include glucose dysregulation, future cardiovascular disease, and development of the metabolic syndrome (Chia and Boston 2006); it may also have psychosocial consequences resulting from lowered self-esteem and social isolation (Puhl and Latner, 2007).…”

Section: Introductionmentioning

confidence: 99%

Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

Hoekstra

Troost²,

Lahuis

et al. 2010

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age-and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, flexible-dose risperidone treatment (mean dose: 1.70 mg/day) in 32 youths with pervasive developmental disorder (mean age ¼ 8.74, range ¼ 5-16 years) in relation to À759C/T 5-hydroxytryptamine 2C receptor (HTR2C) promoter and rs1414334 HTR2C intragenic C/G alleles, along with gender, age, and risperidone dose, using repeated measures analyses of variance. Carriers of the HTR2C promoter T allele gained an average of 0.043 AE 0.017 body mass index-standardized z scores (1.84 AE 1.51 kg) versus 0.64 AE 0.35 z (3.23 AE 1.47 kg) for non-T-allele carriers ( p < 0.001). Presence of the rs1414334 C allele played no significant role. Further, weight gain appeared to be associated with younger age and higher doses of risperidone. The current preliminary findings suggest that the variant T allele of the À759C/T HTR2C promoter polymorphism is protective against risperidone-induced weight gain. Younger children and those treated with higher doses of risperidone may be at higher risk for weight gain.

show abstract

Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents

Cited by 53 publications

References 36 publications

Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey

Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

Contact Info

Product

Resources

About